News | April 25, 2025
We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer
Bayer expects 2025 to be the most difficult year of its turnaround
Bayer expects 2025 to be the most difficult year of its turnaround
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
Consequent to this appointment, Sarosh Shetty ceases to be Interim CEO of ICH.
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
Konieczny has served as Interim CEO since April 2024
Subscribe To Our Newsletter & Stay Updated
